Date: 06 Jan 2011
Infrared Assessment of Bone Quality: A Review
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Bone strength depends on both bone quantity and quality. The former is routinely estimated in clinical settings through bone mineral density measurements but not the latter. Bone quality encompasses the structural and material properties of bone. Although its importance is appreciated, its contribution in determining bone strength has been difficult to precisely quantify partly because it is multifactorial and requires investigation of all bone hierarchical levels. Fourier transform infrared spectroscopy provides one way to explore these levels.
The purposes of our review were to (1) provide a brief overview of Fourier transform infrared spectroscopy as a way to establish bone quality, (2) review the major bone material parameters determined from Fourier transform infrared spectroscopy, and (3) review the role of Fourier transform infrared microspectroscopic analysis in establishing bone quality.
We used the ISI Web of Knowledge database initially to identify articles containing the Boolean term “infrared” AND “bone.” We then focused on articles on infrared spectroscopy in bone-related journals.
Infrared spectroscopy provides information on bone material properties. Their microspectroscopic versions allow one to establish these properties as a function of anatomic location, mineralization extent, and bone metabolic activity. It provides answers pertaining to the contribution of mineral to matrix ratio, mineral maturity, mineral carbonate substitution, and collagen crosslinks to bone strength. Alterations of bone material properties have been identified in disease (especially osteoporosis) not attainable by other techniques.
Infrared spectroscopic analysis is a powerful tool for establishing the important material properties contributing to bone strength and thus has helped better understand changes in fragile bone.
One or more of the authors (EPP) has received consultancies from Procter & Gamble Pharmaceuticals (Cincinnati, OH), Eli Lilly & Co (Indianapolis, IN), and Novartis AG (Basel, Switzerland) and is a member of the scientific board of Crescent Diagnostics Ltd (London, UK).
Bohic S, Heymann D, Pouezat JA, Gauthier O, Daculsi G. Transmission FT-IR microspectroscopy of mineral phases in calcified tissues. C R Acad Sci III. 1998;321:865–876.PubMed
Boskey AL, Pleshko N, Doty SB, Mendelsohn R. Applications of FT-IR microscopy to the study of mineralization in bone and cartilage. Cell Materials. 1992;2:209–220.
Bullough P. The tissue diagnosis of metabolic bone disease. Orthop Clin North Am. 1990;21:65–79.PubMed
Bullough P. Atlas of Orthopaedic Pathology. New York, NY: Gower Medical Publishing; 1992.
Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O’Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res. 2002;17:192–199.PubMedCrossRef
Dumas P, Jamin N, Teillaud JL, Miller LM, Beccard B. Imaging capabilities of synchrotron infrared microspectroscopy. Faraday Discuss. 2004;126:289–302; discussion 303–311.
Einhorn TA. The bone organ system: form and function. In: Marcus R, Feldman D, Kelsey J, eds. Osteoporosis. New York, NY: Academic Press Inc; 1996.
Fratzl P, Gupta HS, Paschalis EP, Roschger P. Structure and mechanical quality of the collagen-mineral nano-composite in bone. J Mater Chem. 2004;14:2115–2123.CrossRef
Henneman ZJ, Nancollas GH, Ebetino FH, Russell RG, Phipps RJ. Bisphosphonate binding affinity as assessed by inhibition of carbonated apatite dissolution in vitro. J Biomed Mater Res A. 2008;85:993–1000.PubMed
Jepsen KJ, Schaffler MB. Bone mass does not adequately predict variations in bone fragility: a genetic approach. Trans Orthop Res Soc. 2001;26:114.
Lazarev YA, Lazareva AV, Shibnev A, Esipova NG. Infrared-spectra and structure of synthetic polytripeptides. Biopolymers. 1978;17:1197–1214.CrossRef
Li C, Paris O, Siegel S, Roschger P, Paschalis E, Klaushofer K, Fratzl P. Strontium is incorporated into mineral crystals only in newly formed bone during strontium ranelate treatment. J Bone Miner Res. 2010;25:968–975.PubMed
Marcott C, Reeder RC, Paschalis EP, Tatakis DN, Boskey AL, Mendelsohn R. Infrared microspectroscopic imaging of biomineralized tissues using a mercury-cadmium-telluride focal-plane array detector. Cell Mol Biol (Noisy-le-grand). 1998;44:109–115.
Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254–1259.PubMed
Miller LM, Carlson CS, Carr GL, Chance MR. A method for examining the chemical basis for bone disease: synchrotron infrared microspectroscopy. Cell Mol Biol (Noisy-le-grand). 1998;44:117–127.
Miller LM, Vairavamurthy V, Chance MR, Mendelsohn R, Paschalis EP, Betts F, Boskey AL. In situ analysis of mineral content and crystallinity in bone using infrared micro-spectroscopy of the nu(4) PO(4)(3−) vibration. Biochim Biophys Acta. 2001;1527:11–19.PubMed
Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res. 1999;14:1768–1778.PubMedCrossRef
Parfitt AM. Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin Obs Gynecol. 1987;30:789–811.CrossRef
Paschalis EP, DiCarlo E, Betts F, Sherman P, Mendelsohn R, Boskey AL. FTIR microspectroscopic analysis of human osteonal bone. Calcif Tissue Int. 1996;59:480–487.PubMed
Posner AS. Bone mineral on the molecular level. Fed Proc. 1973;32:1933–1937.PubMed
Rey C, Shimizu M, Collins B, Glimcher MJ. Resolution-enhanced Fourier transform infrared spectroscopy study of the environment of phosphate ion in the early deposits of a solid phase of calcium phosphate in bone and enamel and their evolution with age. 2. Investigations in the nu3PO4 domain. Calcif Tissue Int. 1991;49:383–388.PubMedCrossRef
Roschger P, Manjubala I, Zoeger N, Meirer F, Simon R, Li C, Fratzl-Zelman N, Misof B, Paschalis E, Streli C, Fratzl P, Klaushofer K. Bone material quality in transiliac bone biopsies of postmenopausal osteoporotic women after 3 years strontium ranelate treatment. J Bone Miner Res. 2010;25:891–900.PubMedCrossRef
- Infrared Assessment of Bone Quality: A Review
Clinical Orthopaedics and Related Research®
Volume 469, Issue 8 , pp 2170-2178
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. Ludwig Boltzmann Institute of Osteology, Hanusch Hospital of WGKK (Viennese Sickness Insurance Funds), and AUVA (Austrian Social Insurance for Occupational Risks) Trauma Centre Meidling, Vienna, Austria
- 2. Department of Chemistry, Rutgers University, Newark, NJ, USA
- 3. Musculoskeletal Integrity Program, Hospital for Special Surgery, New York, NY, USA